ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SPPI Spectrum Pharmaceuticals Inc

1.03
0.00 (0.0%)
After Hours
Last Updated: 19:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 1.14
Ask Price 0.9785
News -
Day High

Low
0.315

52 Week Range

High
1.36

Day Low
Company Name Stock Ticker Symbol Market Type
Spectrum Pharmaceuticals Inc SPPI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.03 19:00:00
Open Price Low Price High Price Close Price Prev Close
1.03 1.03
Trades Volume Avg Volume 52 Week Range
0 0 - 0.315 - 1.36
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.03 USD

Spectrum Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 211.42M - - - 7,742.09
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Spectrum Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SPPI Message Board. Create One! See More Posts on SPPI Message Board See More Message Board Posts

Historical SPPI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months1.071.12990.926851.021,211,658-0.04-3.74%
1 Year0.461.360.3150.86595621,887,9830.57123.91%
3 Years4.765.240.3151.692,925,001-3.73-78.36%
5 Years14.5714.650.3152.722,332,657-13.54-92.93%

Spectrum Pharmaceuticals Description

Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor G-CSF for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer NSCLC tumors with various mutations.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com